Explore Our Biomarker Menu

Biomarker:

CX3CL1

Biological or Clinical Significance:

CX3CL1/Fractalkine acts as a ligand for both CX3CR1 and integrins. It binds to CX3CR1 and to integrins ITGAV:ITGB3 and ITGA4:ITGB1. It can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner. In the presence of CX3CR1, it activates integrins by binding to the classical ligand-binding site (site 1) in integrins. In the absence of CX3CR1, it binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1.

It soluble form is chemotactic for T-cells and monocytes and not for neutrophils. The membrane-bound form promotes adhesion of those leukocytes to endothelial cells. Investigators believe it may play a role in regulating leukocyte adhesion and migration processes at the endothelium. 

References:

Analyte:

CX3CL1

Matrix:

Human Serum

Status:

Experienced Running

Sensitivity-LLOQ:

56.0 pg/mL

Sensitivity-ULOQ:

platform

Ella

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.